Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Jazz Pharmaceuticals plc JAZZ

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).


NDAQ:JAZZ - Post by User

Post by Wrywisdomon Jul 13, 2022 2:02pm
81 Views
Post# 34821442

ENTG Extends Primary Credit Facility with BMO/Others 2+Years

ENTG Extends Primary Credit Facility with BMO/Others 2+YearsFor those not aware, Entourage has extended and improved it's primary credit facility with Bank of Montreal for two more years, furthering it's relationship with one of Canada's most prestigious and established financial institutions. 

It also has extended it's agreements with secondary lenders beyond two years, with the flexibility to pay only interest at the discretion of Entourage.

Add to that revenues soaring every quarter (now more than 60 million dollars over the past 4 quarters), and they are firmly positioned to implement the entirety of their extraordinariy multifaceted strategy in the recreational and medical markets;  as well as furthering their synergies with Boston Beer, Mary's Medicinals, Fire and Flower, and much more. 

https://stockhouse.com/news/press-releases/2022/07/04/entourage-health-announces-amendments-to-its-credit-facilities-to-improve-debt

ENTG Revenues  should exceed expenses by the autumn as the growth and expansion phase winds down, and the revenues from expanded production tiers soar.

Simply a stellar opportunity here.
<< Previous
Bullboard Posts